Gerresheimer has agreed to sell its US prescription drug dispensing packaging business and its global pharmaceutical plastics packaging business to private equity firm Apax Funds in a deal with an enterprise value of approximately €1.5 billion ($1.71bn), including debt.
The transaction covers Centor US Holding Inc and Gerresheimer’s global Primary Packaging Plastics business.
It includes the Centor manufacturing site in the US and a further 15 primary pharmaceutical plastics packaging production sites across nine countries.
Together, the two businesses generated revenue of approximately €570 million ($648.5m) in 2025 and employed around 2,400 people.
The company said it intends to use the expected cash proceeds to optimise its capital and financing structure.
Period of difficulty
The sale follows a turbulent period for Gerresheimer, which recently underwent an internal review of its accounting practices. The subsequent delay in its financial reporting led to the company’s removal from Deutsche Boerse’s SDAX small-cap index.
Germany’s financial regulator BaFin, meanwhile, has instigated audits into Gerresheimer’s financial statements.
Gerresheimer said the sale of Centor is expected to complete by the end of its 2026 financial year, while the sale of the global Primary Packaging Plastics business is expected to close during the first half of its 2027 financial year.
Anders Meyerhoff, partner at Apax, said: “Centor and Primary Packaging Plastics are market leaders in prescription vials and primary pharmaceutical packaging, built on a decades-long reputation for quality and reliability.
“Healthcare packaging plays a critical role in patient safety, with Centor’s and Primary Packaging Plastics’ products used to dispense medicines safely to millions of patients every day.”
Mehmet Tar, principal at Apax, added: “As an independent company backed by the Apax Funds, the business will have the capital to invest in capacity, innovation and US expansion, building on its global leadership.”


